Jennifer Buell: Tune-in: MiNK Therapeutics to unveil pioneering data on the novel armored FAP-CAR-INKT (MiNK-215) at AACR Meeting, April 8

Jennifer Buell, President and Chief Executive Officer at MiNK Therapeutics, shared a post by MiNK Therapeutics on X, adding the following:

“Tune-in: MiNK Therapeutics to unveil pioneering data on the novel armored FAP-CAR-INKT (MiNK-215) at AACR Meeting, April 8. Designed to tackle colorectal cancer liver metastases.”

Quoting MiNK Therapeutic’s post:

“Stay tuned for MiNK’s upcoming presentation at AACR24. On April 8, MiNK will present preclinical data on MiNK-215, our IL-15 armored FAP-targeting CAR-iNKT cell therapy, demonstrating its unique potential against liver metastases in MSS CRC.

Learn more.”

Source: Jennifer Buell/X and MiNK Therapeutics/X